Clinical trials: Acromegaly
Acromegaly
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
Evaluate the efficacy, safety and tolerability of the octreotide implant in patients with acromegaly that were previously treated with octreotide depot.
- Trial name
- NCT00765323
- Testing
- Octreotide Implant, Sandostatin LAR Depot
- Where
- 47 sites in United States, Czechia and 7 more
- Volunteers
- 169 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Acromegaly
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
This is a long term study to evaluate the safety, tolerability and efficacy of an Octreotide Implant in patients that were previously treated with an Octreotide implant.
- Trial name
- NCT01295060
- Testing
- Octreotide
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Acromegaly
Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients
Currently, the first line treatment for acromegaly is surgery, in order to remove the adenoma causing overproduction of growth hormone which leads to acromegaly.
- Trial name
- NCT00128232
- Testing
- Octreotide LAR
- Volunteers
- 100 people
- Sponsor
- Novartis
Acromegaly
Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas
The purpose of this study is to evaluate the efficacy of octreotide acetate to decrease GH and IGF-I levels in acromegalic patients, with microadenomas (≤ 10 mm) or macroadenomas (> 10 mm).
- Trial name
- NCT00242541
- Testing
- Octreotide acetate
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly
Currently, the first line treatment for acromegaly is surgery, in order to remove the adenoma causing overproduction of growth hormone which leads to acromegaly.
- Trial name
- NCT00225979
- Testing
- Octreotide LAR
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Open Label Study of Octreotide Implant in Patients With Acromegaly
To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) response of a hydrated and non-hydrated 84 mg octreotide implant in patients with acromegaly in the first 6 weeks of treatment.
- Trial name
- NCT00913055
- Testing
- octreotide acetate
- Volunteers
- 34 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Acromegaly
Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
This study evaluated the safety and efficacy of an increased frequency of octreotide acetate injections or an increase in dose in partially responsive acromegalic patients with persistently uncontrolled disease.
- Trial name
- NCT00372697
- Testing
- Octreotide acetate 30 mg suspension
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
The purpose of this study is to assess the safety profile of a new prolonged release formulation of octreotide acetate, C2L-OCT-01 PR, administered intra muscularly every 4, 5 or 6 weeks in acromegalic patients.
- Trial name
- NCT00642421
- Testing
- C2L-OCT-01 PR, 10 or 20 mg, C2L-OCT-01 PR, 20 mg
- Where
- 10 sites in United States, Belarus and 4 more
- Volunteers
- 40 people
- Sponsor
- Ambrilia Biopharma, Inc.
Acromegaly
Non Interventional Study For Patients Treated With Somavert®
This open-label, national, prospective, observational, non-interventional, multi-center, post marketing surveillance study was performed in order to examine the efficacy and safety of Somavert® in treatment of subjects with…
- Trial name
- GPOS (NCT00858143)
- Testing
- Non Interventional Observation
- Volunteers
- 311 people
- Sponsor
- Pfizer
Acromegaly
Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
The purpose of this study is to assess the safety profile of C2L-OCT-01 PR for up to an additional 96-week period in acromegalic patients who completed the C2L-OCT-01 PR-301 study.
- Trial name
- NCT00635765
- Testing
- C2L-OCT-01 PR 30 mg
- Where
- 6 sites in Belarus, Hungary and 4 more
- Volunteers
- 63 people
- Sponsor
- Ambrilia Biopharma, Inc.
Acromegaly
Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients
The purpose of this study is to assess the biological safety and efficacy of using the drug, C2L-OCT-01 PR, 30 mg to treat acromegalic patients.
- Trial name
- NCT00616551
- Testing
- C2L-OCT-01 PR, 30 mg, Octreotide acetate prolonged release, 30 mg
- Where
- 6 sites in Belarus, Hungary and 4 more
- Volunteers
- 65 people
- Sponsor
- Ambrilia Biopharma, Inc.
Acromegaly
Long Term Study With B2036-PEG
Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.
- Trial name
- NCT00143416
- Testing
- Pegvisomant
- Where
- 8 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Pfizer
Acromegaly
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the safety and tolerability of SOMAVERT.
- Trial name
- NCT00151437
- Testing
- Pegvisomant treatment, Medical History, demographics, Sign and symptoms: questionnaire
- Where
- 5 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Pfizer
Acromegaly
Pegvisomant And Sandostatin LAR Combination Study
The purpose of this study is to compare the safety and tolerability of combination therapy with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.
- Trial name
- NCT00068029
- Testing
- Pegvisomant/ Sandostatin LAR, Sandostatin LAR, Pegvisomant
- Where
- 33 sites in United States, Australia and 10 more
- Volunteers
- 75 people
- Sponsor
- Pfizer
Acromegaly
A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
The purpose of the study is to determine if Pegvisomant is more efficacious than Sandostatin LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.
- Trial name
- NCT00068042
- Testing
- Pegvisomant, Sandostatin LAR
- Where
- 55 sites in United States, Australia and 11 more
- Volunteers
- 100 people
- Sponsor
- Pfizer